Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

APP to Begin Shipping Pamidronate Disodium for Injection in 2nd

                         Quarter Of 

LOS ANGELES, Nov. 27 /PRNewswire/ -- American Pharmaceutical Partners, Inc. (APP) announced today that patent litigation filed against it by Novartis Corporation regarding APP's Pamidronate product has been resolved with a finding that APP's product does not infringe the Novartis patent on Pamidronate. APP has already received its' tentative approval from the Food and Drug Administration (FDA) and plans to begin shipping Pamidronate Disodium for Injection, USP, in the first half of 2002. Pamidronate is the generic alternative to Aredia(R), marketed by Novartis Pharmaceuticals, a bone-resorption inhibitor indicated for the treatment of hypercalcemia associated with malignancy, for Paget's disease, and for osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. Aredia had U.S. sales of over $445 million in 2000, according to IMS Healthcare.

(Photo: )

Pamidronate will be bar coded at the individual unit of use level, in an attempt to increase patient safety by reducing the frequency of medical errors.

American Pharmaceutical Partners, Inc., is a privately held integrated pharmaceutical company with over 800 employees. APP is one of the leading manufacturers and marketers of injectable pharmaceuticals in the United States with facilities in Los Angeles, California; Schaumburg, Illinois, Melrose Park, Illinois, Grand Island, New York, Bensenville, Illinois and Toronto, Canada. For more information on the Company, visit APP's web site at

The statements in this release regarding sales of Pamidronate and APP's product line may be considered forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those suggested or indicated by such forward-looking statements. These include, among others, the date APP launches this product, the market acceptance of Pamidronate, the sales and financial performance in future periods of this product, the ability of APP to successfully manufacture this product in a time-sensitive and cost effective way, the success of our competitors to more effectively market and sell comparable or competing products, and general economic and regulatory conditions in our industry.


SOURCE American Pharmaceutical Partners, Inc.

-0- 11/27/2001

/CONTACT: Jeffrey M. Yordon, Chief Operating Officer, +1-847-330-1389, or Derek Brown, Chief Operating Officer, +1-310-470-4222, both of American Pharmaceutical Partners, Inc./

/Photo: /

/Web site: /

CO: American Pharmaceutical Partners, Inc. ST: California, Illinois IN: HEA MTC SU: PDT LAW

-0- Nov/27/2001 15:50 GMT

Sponsored Links
Sponsored Links